Friedemann P.
- Country
- Germany
- Department
- AG Klinische Neuroimmunologie
Research Overview
- Phase 3 Extension Study on Long-term Safety and Tolerability of Tolebrutinib in Relapsing and Progressive Multiple Sclerosis
- Evaluation of KYV-101 Anti-CD19 CAR T-Cell Therapy in Refractory Primary and Secondary Progressive Multiple Sclerosis: A Phase 2 Randomized Study
- Evaluation of Safety and Efficacy of CLS12311 in Patients with Relapsing Remitting Multiple Sclerosis: A Phase Ib/IIa Multicenter Study
Data & Insights
Has run more than one trial at 85 of 184 partner sites.
Specializations
Multiple Sclerosis Research
Specializes in advanced therapeutic approaches for progressive forms of multiple sclerosis, with particular emphasis on both primary and secondary progressive variants.
- CAR T-cell therapy applications
- Anti-CD19 targeted treatments
- Progressive MS management
Focuses on innovative cellular therapy approaches for treatment-resistant MS cases.
Neurological Therapeutics
Investigates novel therapeutic compounds including Bruton's Tyrosine Kinase inhibitors for neurological conditions, with specific attention to their long-term safety profiles.
- BTK inhibitor applications
- Long-term treatment safety
- Disease progression markers
Explores therapeutic interventions for various nervous system disorders.
Autoimmune Disorders
Studies innovative treatments for myelin oligodendrocyte glycoprotein antibody-associated disease and related neuroimmunological conditions.
- MOGAD therapeutics
- Antibody-based treatments
- Neuroimmunological disorders
Explores targeted immunological interventions for rare neurological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.